1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors

1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors

Bibliographic Details
Main Authors: Yang Xu, Alexander Starodub, Cesar Perez, Yuping Li, Andrae Vandross, Jason Henry, Alexander I Spira, Xuebin Liao
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items